Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Breast Cancer|Hormone Receptor Positive Tumor|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Locally Advanced Malignant Neoplasm
Interventions: DRUG: Everolimus|DRUG: Exemestane|DRUG: Fulvestrant
Sponsor: Consorzio Oncotech
Collaborators: Clinical Research Technology S.r.l.